Total Payments
$485.69
2024 Payments
$213.11
Companies
11
Transactions
23
Medicare Patients
1,163
Medicare Billing
$125,583
Payment Breakdown by Category
Food & Beverage$468.95 (96.6%)
Education$16.74 (3.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $468.95 | 22 | 96.6% |
| Education | $16.74 | 1 | 3.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $133.20 | 6 | $0 (2024) |
| PFIZER INC. | $97.08 | 5 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $52.83 | 3 | $0 (2023) |
| Lilly USA, LLC | $50.42 | 2 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.96 | 1 | $0 (2024) |
| QOL Medical, LLC | $23.62 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $23.38 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $22.12 | 1 | $0 (2024) |
| Ironwood Pharmaceuticals, Inc | $20.58 | 1 | $0 (2023) |
| Ardelyx, Inc. | $18.97 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $213.11 | 9 | ABBVIE INC. ($73.26) |
| 2023 | $196.33 | 10 | ABBVIE INC. ($59.94) |
| 2022 | $21.46 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($21.46) |
| 2021 | $38.05 | 2 | PFIZER INC. ($38.05) |
| 2019 | $16.74 | 1 | PFIZER INC. ($16.74) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: Immunology | ||||||
| 12/10/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $30.53 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $17.45 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/12/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: Immunology | ||||||
| 10/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: Gastroenterology | ||||||
| 06/27/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.28 | General |
| Category: IMMUNOLOGY | ||||||
| 02/13/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $23.38 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/09/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $21.10 | General |
| Category: Immunology | ||||||
| 10/17/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/10/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: IMMUNOLOGY | ||||||
| 08/01/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/11/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: IMMUNOLOGY | ||||||
| 06/13/2023 | QOL Medical, LLC | Sucraid (Drug) | Food and Beverage | Cash or cash equivalent | $23.62 | General |
| Category: THERAPY FOR CSID | ||||||
| 04/12/2023 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: IMMUNOLOGY | ||||||
| 02/21/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.53 | General |
| Category: Neuroscience | ||||||
| 01/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/18/2023 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $20.58 | General |
| Category: GI | ||||||
| 01/10/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/08/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/16/2021 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/29/2021 | PFIZER INC. | XELJANZ (Drug), INFLECTRA | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/03/2019 | PFIZER INC. | XELJANZ (Drug) | Education | In-kind items and services | $16.74 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 147 | 147 | $108,699 | $17,880 |
| 2022 | 4 | 168 | 168 | $118,825 | $20,148 |
| 2021 | 9 | 438 | 457 | $192,221 | $46,321 |
| 2020 | 11 | 410 | 431 | $173,846 | $41,235 |
Total Patients
1,163
Total Services
1,203
Medicare Billing
$125,583
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 53 | 53 | $42,400 | $8,749 | 20.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 26 | 26 | $15,600 | $2,898 | 18.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 39 | 39 | $29,250 | $2,793 | 9.5% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 14 | 14 | $12,824 | $2,466 | 19.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 15 | 15 | $8,625 | $974.05 | 11.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 60 | 60 | $48,000 | $9,854 | 20.5% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 41 | 41 | $24,600 | $5,269 | 21.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 44 | 44 | $33,000 | $3,548 | 10.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 23 | 23 | $13,225 | $1,477 | 11.2% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 75 | 75 | $45,000 | $10,301 | 22.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 50 | 51 | $40,800 | $9,085 | 22.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 64 | 64 | $48,000 | $7,254 | 15.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 89 | 104 | $11,024 | $6,533 | 59.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 49 | 52 | $8,164 | $4,304 | 52.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 39 | 39 | $22,425 | $2,904 | 12.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 32 | 32 | $5,184 | $2,395 | 46.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 22 | 22 | $5,324 | $1,961 | 36.8% |
| 43249 | Balloon dilation of esophagus, stomach and upper small bowel using a flexible endoscope | Facility | 2021 | 18 | 18 | $6,300 | $1,586 | 25.2% |
| 45378 | Diagnostic examination of large bowel using an endoscope | Facility | 2020 | 51 | 51 | $30,600 | $7,008 | 22.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope | Facility | 2020 | 39 | 39 | $31,200 | $6,609 | 21.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 57 | 72 | $10,944 | $5,520 | 50.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 46 | 46 | $10,810 | $4,895 | 45.3% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 44 | 44 | $33,000 | $4,316 | 13.1% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 50 | 53 | $30,475 | $3,883 | 12.7% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 40 | 40 | $6,320 | $2,645 | 41.9% |
About Dr. Craig Harris, MD
Dr. Craig Harris, MD is a Gastroenterology healthcare provider based in North Ridgeville, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1407877707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Harris, MD has received a total of $485.69 in payments from pharmaceutical and medical device companies, with $213.11 received in 2024. These payments were reported across 23 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($468.95).
As a Medicare-enrolled provider, Harris has provided services to 1,163 Medicare beneficiaries, totaling 1,203 services with total Medicare billing of $125,583. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology, Gastroenterology
- Location North Ridgeville, OH
- Active Since 07/21/2006
- Last Updated 12/21/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1407877707
Products in Payments
- XELJANZ (Drug) $97.08
- SKYRIZI (Biological) $59.94
- RINVOQ (Biological) $55.81
- ENTYVIO (Biological) $52.83
- OMVOH (Drug) $50.42
- XIFAXAN (Drug) $24.96
- Sucraid (Drug) $23.62
- DIFICID (Drug) $23.38
- TREMFYA (Drug) $22.12
- Linzess (Drug) $20.58
- IBSRELA (Drug) $18.97
- ZEPOSIA (Drug) $18.53
- CREON (Drug) $17.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.